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Role of transcription-regulating kinase CDK8 in colon cancer
metastasis
Jiaxin Liang, Mengqian Chen, Eugenia V. Broude and Igor B. Roninson
While the best-known members of the cyclindependent kinase (CDK) family, such as CDK1, CDK2,
CDK4/6, regulate cell cycle progression, many other
CDKs play no direct role in cell cycle transitions and
instead are involved in transcription or RNA splicing. One
of these transcriptional kinases, CDK8 (expressed nearly
universally), together with its closely related paralog
CDK19 (expressed in a tissue-specific pattern), has a
unique function of preferentially regulating transcription
of newly activated genes, acting in conjunction with
various transcription-initiating factors, such as Wnt/βcatenin [1], serum response network, HIF1A [2], TGFβ/
Smad [3], ERα [4], STAT1 and NFκB [5]. As a result,
CDK8/19 inhibition has only minor effects on basal
transcription but attenuates signal-induced activation of
genes that are not expressed in the absence of the signal.
CDK8 has been first linked to cancer when it was
identified as an oncogene that is frequently amplified
or overexpressed in colon carcinoma [1]. Subsequently,
CDK8 has been implicated as a tumor-promoting factor
in breast, pancreatic and prostate cancers, melanoma
and leukemia [6,7]. CDK8 inhibition was also found
to stimulate natural killer cells and to increase innate
immunity [8]. Importantly, CDK8 was identified as
a mediator of chemotherapy- or radiation-induced
expression of genes implicated in cancer metastasis and
drug resistance [9]. CDK8/19 has become an actively
pursued drug target [6] and the first selective CDK8/19
inhibitor, Senexin B, has recently entered clinical trials.
These trials were designed on the basis of preclinical
studies where this compound suppressed the growth of
estrogen-receptor-positive breast cancers when combined
with hormone therapy [4].
Despite the initial reports that CDK8 knockdown
by shRNA in colon cancer cells with CDK8 amplification
or overexpression inhibited cell proliferation [1], several
groups found that CDK8/19 kinase inhibitors have no
significant effect on colon cancer cell growth [8,9].
Nevertheless, CDK8 is one of the most frequently
amplified genes in clinical colon cancers and elevated
CDK8 expression is associated with shorter patient
survival. To reconcile these paradoxical observations,
we have recently carried out a systematic analysis of the
effects of CDK8 knockdown or kinase inhibition on colon
cancer cell growth in culture, at different primary tumor
sites, as well as in the liver, the primary site of metastasis
and the leading cause of colon cancer mortality [10].
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In cell culture assays, CDK8/19 kinase inhibition
by Senexin B had no effect on short-term growth in three
different CDK8-overexpressing human colon cancer cell
lines, in two of which CDK8 gene was amplified, whereas
only one of the three cell lines showed a significant
response in the long-term clonogenic assay. Furthermore,
in contrast to previous reports comparing the growth
of CDK8-overexpressing colon cancer cells with their
derivatives with stable CDK8 knockdown [1], CDK8
knockdown by inducible shRNA expression had no effect
on cell growth or colony formation. In subsequent studies,
which were conducted primarily in a transplantable murine
CT26 colon cancer model, CDK8 knockdown or kinase
inhibition were found to have no significant effect on
primary tumor growth in mice when the tumor cells were
implanted subcutaneously, orthotopically (in the cecum) or
in the spleen. In contrast, the growth of tumors that arise
in the liver following splenic injection of colon cancer
cells, was strongly suppressed by CDK8 knockdown in
tumor cells or by treating mice with Senexin B. Selective
inhibition of tumor growth in the liver (but not at the
primary injection site) was also observed in the CDK8overexpressing human HCT116 colon cancer cells.
Importantly, CDK8/19 inhibitor treatment, when started
after liver metastases have been already established,

Figure 1: Mechanism of the effect of CDK8 on
metastatic growth of colon cancer in the liver.
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inhibited the growth of metastatic tumors and extended
mouse survival.
The mechanism of the effect of CDK8 in promoting
colon cancer growth in the liver is illustrated in Figure
1. This effect was found to be mediated primarily by the
inhibition of expression of extracellular matrix protein
TIMP3, which has been implicated in the suppression
of invasive growth and angiogenesis. CDK8 suppresses
TIMP3 expression by stimulating TGFβ/SMAD-driven
transcription of a TIMP3-targeting microRNA, miR-181b,
providing a new and potentially general mechanism for
negative regulation of gene expression by CDK8. Another
effect that contributed to the pro-metastatic activity of
CDK8 was the induction of the expression of certain
matrix metalloproteinases (MMPs), notably MMP3 in
murine and MMP9 in human cells, via the potentiating
effect of CDK8 on Wnt/β-catenin-driven transcription.
These findings [10] suggest the utility of CDK8 inhibitors
for the treatment of colon cancer metastases in the liver
and their potential use in other therapeutic settings that
involve TGFβ/SMAD or Wnt/β-catenin pathways.
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